Turcotte M - Search Results

1

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.

Allard B, Turcotte M, Stagg J. Allard B, et al. Among authors: turcotte m. Expert Opin Ther Targets. 2014 Aug;18(8):863-81. doi: 10.1517/14728222.2014.915315. Epub 2014 May 6. Expert Opin Ther Targets. 2014. PMID: 24798880 Review.

2

CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.

Allard B, Turcotte M, Stagg J. Allard B, et al. Among authors: turcotte m. J Biomed Biotechnol. 2012;2012:485156. doi: 10.1155/2012/485156. Epub 2012 Oct 16. J Biomed Biotechnol. 2012. PMID: 23125525 Free PMC article. Review.

3

Anti-CD73 therapy impairs tumor angiogenesis.

Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Allard B, et al. Among authors: turcotte m. Int J Cancer. 2014 Mar 15;134(6):1466-73. doi: 10.1002/ijc.28456. Epub 2013 Sep 18. Int J Cancer. 2014. PMID: 23982901 Free article.

4

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J. Turcotte M, et al. Cancer Res. 2015 Nov 1;75(21):4494-503. doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11. Cancer Res. 2015. PMID: 26363007

5

CD73-adenosine reduces immune responses and survival in ovarian cancer patients.

Gaudreau PO, Allard B, Turcotte M, Stagg J. Gaudreau PO, et al. Among authors: turcotte m. Oncoimmunology. 2016 Jan 19;5(5):e1127496. doi: 10.1080/2162402X.2015.1127496. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467942 Free PMC article.

6

Targeting A2 adenosine receptors in cancer.

Allard D, Turcotte M, Stagg J. Allard D, et al. Among authors: turcotte m. Immunol Cell Biol. 2017 Apr;95(4):333-339. doi: 10.1038/icb.2017.8. Epub 2017 Feb 8. Immunol Cell Biol. 2017. PMID: 28174424 Review.

7

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J. Turcotte M, et al. Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30. Cancer Res. 2017. PMID: 28855210

8

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J. Charlebois R, et al. Among authors: turcotte m. Cancer Res. 2017 Jan 15;77(2):312-319. doi: 10.1158/0008-5472.CAN-16-1873. Epub 2016 Nov 21. Cancer Res. 2017. PMID: 27872096

9

Variation in mitochondrial function in hypoxia-sensitive and hypoxia-tolerant human glioma cells.

Turcotte ML, Parliament M, Franko A, Allalunis-Turner J. Turcotte ML, et al. Br J Cancer. 2002 Feb 12;86(4):619-24. doi: 10.1038/sj.bjc.6600087. Br J Cancer. 2002. PMID: 11870546 Free PMC article.

10

Tn5-induced lipopolysaccharide mutations in Bordetella pertussis that affect outer membrane function.

Turcotte ML, Martin D, Brodeur BR, Peppler MS. Turcotte ML, et al. Microbiology (Reading). 1997 Jul;143 ( Pt 7):2381-2394. doi: 10.1099/00221287-143-7-2381. Microbiology (Reading). 1997. PMID: 9245820 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page